A new study provides a rationale for the use of poly (ADP-ribose) polymerase (PARP) inhibitors to trigger irreparable DNA damage as a therapeutic approach in acute myeloid leukemia (AML). It also provides support for combining PARP inhibitors with agents that reduce HOXA9 protein levels.
This is a preview of subscription content, log in via an institution to check access.
References
Lo-Coco, F. et al. N. Engl. J. Med. 369, 111–121 (2013).
Ley, T.J. et al. Nature 456, 66–72 (2008).
Esposito, M.T., Zhao, L. & So, C.W. Nat. Med. 21, 1481–1490 (2015).
Mateo, J. et al. N. Engl. J. Med. 373, 1697–1708 (2015).
Santos, M.A. et al. Nature 514, 107–111 (2014).
Faber, J. et al. Blood 113, 2375–2385 (2009).
Yang, C. et al. Cancer Res. 75, 1838–1845 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, L., Hamard, PJ. & Nimer, S. PARP inhibitors: a treatment option for AML?. Nat Med 21, 1393–1394 (2015). https://doi.org/10.1038/nm.4007
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4007
- Springer Nature America, Inc.